Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba

PURPOSE: Dual HER2 blockade chemotherapy is the standard of care for localized HER2+ breast cancer (BC). However, despite the efficacy of neoadjuvant therapy, relapses occurring in around 10% of patients highlight the need to improve its clinical approach. Therefore, this study aimed to evaluate the...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Elías A. Gracia Medina, Brenda Benítez Caballero, Karen López Miguel, Zaili Aleaga Gutiérrez, Braulio Mestre Fernández, Luis E. Alsina Tul, Luis E. Martín Rodríguez, Orlando Valdés Guerrero, Idania G. Sánchez Varela, María de la Caridad Campos Bernardo, Yoandri Calderón Montero, Mónica Ramos Ortiz, Julien Martínez Carrasco, Keytia Peña Torres, Yenia I. Díaz Prado, María Caridad Rubio, Inés M. Pérez Braojo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-01-01
coleção:	Cancer Treatment and Research Communications
Assuntos:	Early breast cancer Neoadjuvant Pertuzumab Real-world data Subcutaneous trastuzumab
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2468294222001617
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!